Catridecacog

Jump to: navigation, search


WikiDoc Resources for Catridecacog

Articles

Most recent articles on Catridecacog

Most cited articles on Catridecacog

Review articles on Catridecacog

Articles on Catridecacog in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Catridecacog

Images of Catridecacog

Photos of Catridecacog

Podcasts & MP3s on Catridecacog

Videos on Catridecacog

Evidence Based Medicine

Cochrane Collaboration on Catridecacog

Bandolier on Catridecacog

TRIP on Catridecacog

Clinical Trials

Ongoing Trials on Catridecacog at Clinical Trials.gov

Trial results on Catridecacog

Clinical Trials on Catridecacog at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Catridecacog

NICE Guidance on Catridecacog

NHS PRODIGY Guidance

FDA on Catridecacog

CDC on Catridecacog

Books

Books on Catridecacog

News

Catridecacog in the news

Be alerted to news on Catridecacog

News trends on Catridecacog

Commentary

Blogs on Catridecacog

Definitions

Definitions of Catridecacog

Patient Resources / Community

Patient resources on Catridecacog

Discussion groups on Catridecacog

Patient Handouts on Catridecacog

Directions to Hospitals Treating Catridecacog

Risk calculators and risk factors for Catridecacog

Healthcare Provider Resources

Symptoms of Catridecacog

Causes & Risk Factors for Catridecacog

Diagnostic studies for Catridecacog

Treatment of Catridecacog

Continuing Medical Education (CME)

CME Programs on Catridecacog

International

Catridecacog en Espanol

Catridecacog en Francais

Business

Catridecacog in the Marketplace

Patents on Catridecacog

Experimental / Informatics

List of terms related to Catridecacog

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Catridecacog (brand name Tretten) is a class of recombinant factor XIII A-subunit based medication, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.

References

[2]

[3]


Linked-in.jpg